Video
Dr. Woyach on a Study Combining MOR208 With Lenalidomide for the Treatment of CLL
Author(s):
Jennifer Woyach, MD, associate professor, Ohio State University, discusses a study examining the use of MOR208 combined with lenalidomide (Revlimid) for the treatment of chronic lymphotic leukemia (CLL) during the American Society of Hematology (ASH) Annual Meeting.
Jennifer Woyach, MD, associate professor, Ohio State University, discusses a study examining the use of MOR208 combined with lenalidomide (Revlimid) for the treatment of chronic lymphotic leukemia (CLL) during the American Society of Hematology (ASH) Annual Meeting.
The study includes 4 cohorts of patients — including patients with relapse/refractory CLL, treatment naïve CLL, richter’s transformation, and patients who have received treatment with ibrutinib (Imbruvica) and have developed mutations that will render them resistant to ibrutinib without having clinical progression, Woyach says.
